4//SEC Filing
Zisson Alex 4
Accession 0001213900-21-047814
CIK 0001817944other
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 8:33 PM ET
Size
9.2 KB
Accession
0001213900-21-047814
Insider Transaction Report
Form 4
Zisson Alex
Director10% Owner
Transactions
- Award
Common Stock
2021-09-09+490,531→ 490,531 total(indirect: See Footnote) - Award
Common Stock
2021-09-09+2,470,756→ 5,692,381 total(indirect: See Footnote) - Award
Common Stock
2021-09-09+2,731,094→ 3,221,625 total(indirect: See Footnote)
Footnotes (2)
- [F1]Received pursuant to the Agreement and Plan of Merger, dated as of April 27, 2021 by and among Blue Water Acquisition Corp. (n/k/a Clarus Therapeutics Holdings, Inc.) (the "Issuer"), Blue Water Merger Sub Corp. and Clarus Therapeutics, Inc. ("Legacy Clarus") (the "Merger Agreement") pursuant to which, through a merger, Legacy Clarus became a direct, wholly-owned subsidiary of the Issuer.
- [F2]The Reporting Person is the managing director of H.I.G. Capital LLC, and may be deemed to share voting and investment power with respect to the shares directly held by H.I.G. Ventures -- Clarus LLC (2,731,094 shares of Issuer common stock), H.I.G. Bio -- Clarus II, L.P. (2,470,756 shares of Issuer common stock), and H.I.G. Bio -- Clarus I, L.P. (490,531 shares of Issuer common stock). These three entities are owned by private funds advised by H.I.G. Capital, LLC, an SEC registered investment advisor, and its affiliates.
Documents
Issuer
Clarus Therapeutics Holdings, Inc.
CIK 0001817944
Entity typeother
Related Parties
1- filerCIK 0001512058
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 8:33 PM ET
- Size
- 9.2 KB